explore -WSS

explore

author：explore 2025-09-28 15:06:43 - browse：411

Illustration of a teal cancer cell. -- health coverage from STAT — Illustration of a teal cancer cell. Adobe

Sana Biotechnology, a startup that just a couple of years ago raised over $1 billion off a grand plan to create a portfolio of powerful medicines, said Tuesday it would lay off nearly a third of its employees and de-prioritize one of its most ambitious programs as it looks to save money.

The layoffs are Sana’s second round of cuts in less than a year. It laid off 15% of staff last November after axing another program.

Tuesday’s move pushed back a program focused on turning a patient’s own immune cells into cancer-killing assassins or curing blood disorders such as sickle cell with just an IV infusion. Known as in vivo reprogramming, it was originally the company’s central focus and would have amounted to a monumental breakthrough.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Community Health Systems hospitals under DOJ investigation

WSS

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Why Novartis is changing the name of its research labs

Medicaid rebukes states for mistakenly disenrolling children

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

The Harvard botanist who searched for psychedelics in the Amazon

Trump surgeon general acknowledges mistakes during Covid

explore

explore

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The 10 drugs up first for Medicare price negotiation

Walensky prepares to leave CDC — and Congress — behind

How generative AI is inspiring dreams of a health data revolution

How one medical school became remarkably diverse

Stem cell treatment guidelines are released by FDA

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Listen: Biogen's potential pivot, & Illumina's next chapter

How one medical school became remarkably diverse

Snackable artificial intelligence, expert AI, and the pharma industry

Wikipedia

Alabama frozen embryo ruling has major implications for IVF clinics

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Amazon on where the company's health care bets are headed next

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

A solution to the after

knowledge

hotspot

focus

Wikipedia